Financial reports
10-K
2023 FY
Annual report
25 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
13 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
5 Apr 22
NT 10-K
Notice of late annual filing
1 Apr 22
Current reports
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
15 Feb 24
8-K
Other Events
9 Feb 24
8-K
Other Events
30 Jan 24
8-K
Other Events
8 Jan 24
8-K
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
5 Dec 23
8-K
PAVmed Provides Business Update and Third Quarter Financial Results
14 Nov 23
8-K
Entry into a Material Definitive Agreement
18 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
6 Feb 24
S-8
Registration of securities for employees
6 Feb 24
424B5
Prospectus supplement for primary offering
30 May 23
S-8
Registration of securities for employees
10 Feb 23
S-8
Registration of securities for employees
10 Feb 23
S-8
Registration of securities for employees
13 Apr 22
S-8
Registration of securities for employees
13 Apr 22
424B5
Prospectus supplement for primary offering
4 Apr 22
25-NSE
Exchange delisting
28 Jan 22
424B5
Prospectus supplement for primary offering
10 Jan 22
Proxies
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
PRE 14A
Preliminary proxy
20 Apr 23
DEF 14A
Definitive proxy
21 Feb 23
PRE 14A
Preliminary proxy
8 Feb 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
PRE 14A
Preliminary proxy
22 Apr 22
DEF 14A
Definitive proxy
30 Apr 21
DEF 14A
Definitive proxy
27 Jan 21
Other
EFFECT
Notice of effectiveness
10 Jan 22
CORRESP
Correspondence with SEC
5 Jan 22
UPLOAD
Letter from SEC
27 Dec 21
EFFECT
Notice of effectiveness
18 Sep 20
CORRESP
Correspondence with SEC
14 Sep 20
UPLOAD
Letter from SEC
14 Sep 20
EFFECT
Notice of effectiveness
29 Apr 20
CORRESP
Correspondence with SEC
24 Apr 20
CORRESP
Correspondence with SEC
20 Apr 20
CORRESP
Correspondence with SEC
15 Apr 20
Ownership
4
Timothy E Baxter
23 Feb 24
4
Debra White
23 Feb 24
4
Ronald M Sparks
23 Feb 24
4
Joan B Harvey
23 Feb 24
4
Michael J Glennon
23 Feb 24
4
James L Cox
23 Feb 24
4
Lucid Diagnostics Inc.
20 Feb 24
SC 13D/A
Lucid Diagnostics Inc.
20 Feb 24
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13D/A
Lucid Diagnostics Inc.
2 Feb 24